Guggenheim initiated coverage of Abivax with a Buy rating and $50 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
Questions or Comments about the article? Write to editor@tipranks.com